China Medical System (HKG:0867, SGX:8A8) said its subsidiary Dermavon Holdings received Chinese regulatory approval to conduct a phase 3 trial of MG-K10, according to a Hong Kong bourse filing Sunday.
Shares of the company fell nearly 2% in morning trade Monday.
The drug is being developed for the treatment of a skin condition called chronic spontaneous urticaria.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.